drugset / Trial / NCT02679755

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

NCT02679755

Phase 4 Completed 252 enrolled Pfizer
Non-randomizedOpen-labelTreatment

Summary

A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate.

Timeline

Start
2016-03-09
Primary completion
2019-07-25
Completion
2019-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule 125 mg Oral
Background Letrozole Other / unclassified 2.5 mg Oral